Treatment
-
The Ins and Outs of Tumor TestingIn a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
by Kate Yandell
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Artificial Intelligence Characterizes CancerAt the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
by Kevin McLaughlin
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
A Better Way to Screen for Lynch Syndrome?Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
Liver Cancer on the RiseLiver cancer incidence and death rates are increasing rapidly. Although there is no screening test for the disease, minimizing risk factors—hepatitis B and C, smoking, obesity and type 2 diabetes—could prevent many cases from developing.
by Sue Rochman
-
From the Editor-in-Chief
DNA Profiling Moves From Forensics to DiagnosticsDNA profiling technologies are providing new ways to detect and monitor cancer.
by William G. Nelson, MD, PhD
-
Forward Look
Banking on BacteriaResponse to immunotherapy may be linked to gut microbiome.
by Chris Palmer
-
Forward Look
Improving Cancer Care in Sub-Saharan AfricaNew guidelines account for limited medical resources.
by Cameron Walker
